ProfileGDS5672 / 226773_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
OrganismHomo sapiens


control bevacizumab dibenzazepine GSM958322 GSM958323 GSM958324 GSM958328 GSM958329 GSM958330 GSM958325 GSM958326 GSM958327 73% 72% 72% 72% 71% 71% 71% 71% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM958322U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2]6.9053373
GSM958323U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2]6.8415372
GSM958324U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2]6.8055472
GSM958328U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2]6.8103672
GSM958329U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2]6.6516271
GSM958330U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2]6.4858271
GSM958325U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2]6.6401771
GSM958326U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2]6.5743971
GSM958327U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2]6.7886172